Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment

Abdominal aortic aneurysm (AAA) is a life-threatening condition characterized by the dilation of the abdominal aorta, leading to a high risk of rupture. Current treatment options are limited, particularly for patients ineligible for surgical interventions. This study explores a novel immunotherapeutic approach using chimeric antigen receptor Treg cells targeting vascular cell adhesion molecule-1 (VCAM-1) to mitigate AAA progression. By leveraging the specificity and regulatory function of CAR-Treg cells, our research aims to modulate the immune response and reduce inflammation in the aneurysmal wall. Results from preclinical mouse models demonstrated that CAR-Treg cells effectively homed to the aneurysmal site, suppressed local inflammation, and decreased aortic dilation compared to control groups. These findings suggest that CAR-Treg cell therapy could provide a promising, non-surgical treatment option for AAA patients, addressing a critical unmet need in cardiovascular disease management.

Authors

Institutions

Publication Details

Journal
Communications Biology
Published
2025-08-15
DOI
https://doi.org/10.1038/s42003-025-08604-9
Citations
3
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
3.14

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment

Yuemeng Li, Yu Lun, Dittmar Böckler, Philipp Erhart et al.
3 citations
Communications Biology
CAR-T cell therapy research
3.14
article

Targeting VCAM-1 with chimeric antigen receptor and regulatory T cell for abdominal aortic aneurysm treatment

Yuemeng Li, Yu Lun, Dittmar Böckler, Philipp Erhart, Qingwei Gang, Yuchen He, Yanshuo Han, Shiyue Wang, Xiaoxu Zhang, Jian Zhang, Han Jiang, Jamol Uzokov, Shikai Shen
article en
3 citations

Abstract

Abdominal aortic aneurysm (AAA) is a life-threatening condition characterized by the dilation of the abdominal aorta, leading to a high risk of rupture. Current treatment options are limited, particularly for patients ineligible for surgical interventions. This study explores a novel immunotherapeutic approach using chimeric antigen receptor Treg cells targeting vascular cell adhesion molecule-1 (VCAM-1) to mitigate AAA progression. By leveraging the specificity and regulatory function of CAR-Treg cells, our research aims to modulate the immune response and reduce inflammation in the aneurysmal wall. Results from preclinical mouse models demonstrated that CAR-Treg cells effectively homed to the aneurysmal site, suppressed local inflammation, and decreased aortic dilation compared to control groups. These findings suggest that CAR-Treg cell therapy could provide a promising, non-surgical treatment option for AAA patients, addressing a critical unmet need in cardiovascular disease management.

Communications BiologyVol. 8(1)
Dalian Ocean University (CN), Heidelberg University (DE), Dalian University of Technology (CN), Dalian University (CN), Dalian Municipal Central Hospital (CN), First Hospital of China Medical University (CN), Tashkent Pediatric Medical Institute (UZ), China Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province
Good health and well-being
Openalex Percentile: Top 7%
CAR-T cell therapy research
3.14
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.